Evidence map›Paper›PMID 18703050›Full record

ArticleExperimental cell research2008

Tumor cell migration and invasion are regulated by expression of variant integrin glycoforms.

Faheem M Shaikh, Eric C Seales, William C Clem, Kristin M Hennessy, Ya Zhuo, Susan L Bellis

Open access · greenAbstract read
In one paragraph

Article in Experimental cell research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 87 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. ST6Gal1: Oncogenic signaling pathways and targets.Frontiers in molecular biosciences · 2022
    Review
  7. Article
  8. Review
  9. Altered Actin Dynamics in Cell Migration of GNE Mutant Cells.Frontiers in cell and developmental biology · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Faheem M ShaikhDepartment of Physiology and Biophysics, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
Eric C Seales
William C Clem
Kristin M Hennessy
Ya Zhuo
Susan L Bellis
University of Alabama at Birmingham · USVivo Biosciences (United States) · US

Funding

Regulation of beta1 integrin glycosylation by rasR01CA084248 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BELLIS, SUSAN L · 2002 to 2011
$2.4M
NCI NIH HHS R01 CA084248NCI NIH HHS R01CA84248
6 · The paper itself

Abstract

The ST6Gal-I glycosyltransferase, which adds alpha2-6-linked sialic acids to glycoproteins, is overexpressed in colon adenocarcinoma, and enzyme activity is correlated with tumor cell invasiveness. Previously we reported that forced expression of oncogenic ras in HD3 colonocytes causes upregulation of ST6Gal-I, leading to increased alpha2-6 sialylation of beta1 integrins. To determine whether ras-induced sialylation is involved in promoting the tumor cell phenotype, we used shRNA to downregulate ST6Gal-I in ras-expressors, and then monitored integrin-dependent responses. Here we show that forced ST6Gal-I downregulation, leading to diminished alpha2-6 sialylation of integrins, inhibits cell adhesion to collagen I, a beta1 ligand. Correspondingly, collagen binding is reduced by enzymatic removal of cell surface sialic acids from ras-expressors with high ST6Gal-I levels (i.e., no shRNA). Cells with forced ST6Gal-I downregulation also exhibit decreased migration on collagen I and diminished invasion through Matrigel. Importantly, GD25 cells, which lack beta1 integrins (and ST6Gal-I), do not demonstrate differential invasiveness when forced to express ST6Gal-I, suggesting that the effects of variant sialylation are mediated specifically by beta1 integrins. The observation that cell migration and invasion can be blocked in oncogenic ras-expressing cells by forcing ST6Gal-I downregulation implicates differential sialylation as an important ras effector, and also suggests that ST6Gal-I is a promising therapeutic target.

Indexed as

Colonic NeoplasmsNeoplasm InvasivenessAdenocarcinomaAnimalsbeta-D-Galactoside alpha 2-6-SialyltransferaseCell AdhesionCell Line, TumorCell MovementCollagen Type IHumansIntegrinsMiceNeuraminidaseProtein Isoformsras ProteinsSialic Acidsbeta-D-Galactoside alpha 2-6-SialyltransferaseCollagen Type IIntegrinsNeuraminidaseProtein Isoformsras ProteinsSialic AcidsSialyltransferases

Identifiers

PMID18703050
PMCPMC2570357
OpenAlexW2127890764

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.